Breast Cancer Coverage from Every Angle

Elizabeth A. Mittendorf, MD, PhD, and Lisa A. Carey, MD, on Chemoendocrine Treatment in Breast Cancer: the TAILORx Trial

Posted: Monday, June 11, 2018

Elizabeth A. Mittendorf, MD, PhD, of Dana-Farber/Brigham and Women’s Cancer Center, and Lisa A. Carey, MD, of the University of North Carolina, discuss the impact of new phase III findings on chemoendocrine treatment vs endocrine treatment alone in hormone receptor–positive, HER2-negative, node-negative breast cancer.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.